We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bellicum Pharmaceuticals Inc | NASDAQ:BLCM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.25 | 0.20 | 0.50 | 0 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * BAKER BROS. ADVISORS LP |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [BLCM] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below) | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 21912 | I | See Footnotes (1)(2)(3) |
Common Stock | 227211 | I | See Footnotes (2)(3)(4) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Warrants (right to buy) | (5)(6)(7) | (8) | Common Stock | 1462729 | $0.0001 | I | See Footnotes (2)(3)(9) |
Warrants (right to buy) | (5)(6)(7) | (8) | Common Stock | 16159451 | $0.0001 | I | See Footnotes (2)(3)(10) |
Warrants (right to buy) | (11) | (12) | Common Stock | 127850 | $0.001 | I | See Footnotes (2)(3)(9) |
Warrants (right to buy) | (11) | (12) | Common Stock | 1531902 | $0.001 | I | See Footnotes (2)(3)(10) |
Series 1 Convertible Non-Voting Preferred Stock | (13)(14) | (13)(14) | Common Stock | 371860 | (13) | I | See Footnotes (2)(3)(9) |
Series 1 Convertible Non-Voting Preferred Stock | (13)(14) | (13)(14) | Common Stock | 4108140 | (13) | I | See Footnotes (2)(3)(10) |
Warrants (right to buy) | (15) | 11/3/2025 | Common Stock | 127850 | $6.50 | I | See Footnotes (2)(3)(9) |
Warrants (right to buy) | (15) | 11/3/2025 | Common Stock | 1531902 | $6.50 | I | See Footnotes (2)(3)(10) |
Warrants (right to buy) | (16) | 12/7/2028 | Common Stock | 146272 | $1.69 | I | See Footnotes (2)(3)(9) |
Warrants (right to buy) | (16) | 12/7/2028 | Common Stock | 1615945 | $1.69 | I | See Footnotes (2)(3)(10)(16) |
Warrants (right to buy) | (17) | 8/21/2026 | Common Stock or Series 1 Preferred | 371860 | (17) | I | See Footnotes (2)(3)(9) |
Warrants (right to buy) | (17) | 8/21/2026 | Common Stock or Series 1 Preferred | 4108140 | (17) | I | See Footnotes (2)(3)(10) |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
BAKER BROS. ADVISORS LP 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | ||||
BAKER JULIAN 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | ||||
BAKER FELIX 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X | ||||
Baker Bros. Advisors (GP) LLC 860 WASHINGTON STREET, 3RD FLOOR NEW YORK, NY 10014 | X |
Signatures | ||
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 5/5/2023 | |
**Signature of Reporting Person | Date | |
/s/ Julian C. Baker | 5/5/2023 | |
**Signature of Reporting Person | Date | |
/s/ Felix J. Baker | 5/5/2023 | |
**Signature of Reporting Person | Date | |
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 5/5/2023 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Bellicum Pharmaceuticals Chart |
1 Month Bellicum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions